1
|
Kenny SE, Antaw F, Locke WJ, Howard CB, Korbie D, Trau M. Next-Generation Molecular Discovery: From Bottom-Up In Vivo and In Vitro Approaches to In Silico Top-Down Approaches for Therapeutics Neogenesis. Life (Basel) 2022; 12:life12030363. [PMID: 35330114 PMCID: PMC8950575 DOI: 10.3390/life12030363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 02/23/2022] [Indexed: 12/02/2022] Open
Abstract
Protein and drug engineering comprises a major part of the medical and research industries, and yet approaches to discovering and understanding therapeutic molecular interactions in biological systems rely on trial and error. The general approach to molecular discovery involves screening large libraries of compounds, proteins, or antibodies, or in vivo antibody generation, which could be considered “bottom-up” approaches to therapeutic discovery. In these bottom-up approaches, a minimal amount is known about the therapeutics at the start of the process, but through meticulous and exhaustive laboratory work, the molecule is characterised in detail. In contrast, the advent of “big data” and access to extensive online databases and machine learning technologies offers promising new avenues to understanding molecular interactions. Artificial intelligence (AI) now has the potential to predict protein structure at an unprecedented accuracy using only the genetic sequence. This predictive approach to characterising molecular structure—when accompanied by high-quality experimental data for model training—has the capacity to invert the process of molecular discovery and characterisation. The process has potential to be transformed into a top-down approach, where new molecules can be designed directly based on the structure of a target and the desired function, rather than performing screening of large libraries of molecular variants. This paper will provide a brief evaluation of bottom-up approaches to discovering and characterising biological molecules and will discuss recent advances towards developing top-down approaches and the prospects of this.
Collapse
Affiliation(s)
- Sophie E. Kenny
- Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Corner of College and Cooper Roads (Bldg 75), Brisbane, QLD 4072, Australia; (S.E.K.); (F.A.); (C.B.H.)
| | - Fiach Antaw
- Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Corner of College and Cooper Roads (Bldg 75), Brisbane, QLD 4072, Australia; (S.E.K.); (F.A.); (C.B.H.)
| | - Warwick J. Locke
- Molecular Diagnostic Solutions, Health and Biosecurity, Commonwealth Scientific and Industrial Research Organisation, Building 101, Clunies Ross Street, Canberra, ACT 2601, Australia;
| | - Christopher B. Howard
- Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Corner of College and Cooper Roads (Bldg 75), Brisbane, QLD 4072, Australia; (S.E.K.); (F.A.); (C.B.H.)
| | - Darren Korbie
- Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Corner of College and Cooper Roads (Bldg 75), Brisbane, QLD 4072, Australia; (S.E.K.); (F.A.); (C.B.H.)
- Correspondence: (D.K.); (M.T.)
| | - Matt Trau
- Centre for Personalised Nanomedicine, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Corner of College and Cooper Roads (Bldg 75), Brisbane, QLD 4072, Australia; (S.E.K.); (F.A.); (C.B.H.)
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
- Correspondence: (D.K.); (M.T.)
| |
Collapse
|
2
|
Melnikov F, Hsieh JH, Sipes NS, Anastas PT. Channel Interactions and Robust Inference for Ratiometric β-lactamase Assay Data: a Tox21 Library Analysis. ACS SUSTAINABLE CHEMISTRY & ENGINEERING 2018; 6:3233-3241. [PMID: 32461840 PMCID: PMC7252516 DOI: 10.1021/acssuschemeng.7b03394] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Ratiometric β-lactamase (BLA) reporters are widely used to study transcriptional responses in a high-throughput screening (HTS) format. Typically, a ratio readout (background/target fluorescence) is used for toxicity assessment and structure-activity modeling efforts from BLA HTS data. This ratio readout may be confounded by channel-specific artifacts. To maximize the utility of BLA HTS data, we analyzed the relationship between individual channels and ratio readouts after fitting 10,000 chemical titration series screened in seven BLA stress-response assays from the Tox21 initiative. Similar to previous observations, we found that activity classifications based on BLA ratio readout alone are confounded by interference patterns for up to 85% (50 % on average) of active chemicals. Most Tox21 analyses adjust for this issue by evaluating target and ratio readout direction. In addition, we found that the potency and efficacy estimates derived from the ratio readouts may not represent the target channel effects and thus complicates chemical activity comparison. From these analyses we recommend a simpler approach using a direct evaluation of the target and background channels as well as the respective noise levels when using BLA data for toxicity assessment. This approach eliminates the channel interference issues and allows for straightforward chemical assessment and comparisons.
Collapse
Affiliation(s)
- Fjodor Melnikov
- School of Forestry and Environmental Studies, Yale University, New Haven, CT 06520, United States
| | - Jui-Hua Hsieh
- Kelly Government Solutions, 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, United States
| | - Nisha S Sipes
- National Toxicology Program / National Institute of Environmental Health Sciences (NIEHS), 111 T.W. Alexander Drive, Research Triangle Park, NC 27709, United States
| | - Paul T Anastas
- School of Forestry and Environmental Studies, Yale University, New Haven, CT 06520, United States
- Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06520, United States
| |
Collapse
|
3
|
Abstract
Creating an automated assay team with multiple skills that can support diverse screening responsibilities is a key challenge for drug discovery research sites. Development of ultra high throughput screening (uHTS) screens, development of lead identification and lead optimization assays within medicinal chemistry supported projects, and automation and miniaturization of assays are best performed by a dedicated team of varying backgrounds, experience, and skill sets. This article discusses how integration with therapeutic franchises, regular communication processes, and formal and informal cross-training facilitate the establishment of a streamlined and efficient model at our site for supporting multiple projects at relatively modest financial outlay and recruitment levels.
Collapse
|
4
|
Sharma H, Kinoshita Y, Fujiu S, Nomura S, Sawada M, Ahmed S, Shibuya M, Shirai K, Takamatsu S, Watanabe T, Yamazaki H, Kamiyama R, Kobayashi T, Arai H, Suzuki M, Nemoto N, Ando K, Uchida H, Kitamura K, Takei O, Nishigaki K. Establishment of a reborn MMV-microarray technology: realization of microbiome analysis and other hitherto inaccessible technologies. BMC Biotechnol 2014; 14:78. [PMID: 25141858 PMCID: PMC4153446 DOI: 10.1186/1472-6750-14-78] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Accepted: 08/15/2014] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND With the accelerating development of bioscience, the problem of research cost has become important. We previously devised and developed a novel concept microarray with manageable volumes (MMV) using a soft gel. It demonstrated the great potential of the MMV technology with the examples of 1024-parallel-cell culture and PCR experiments. However, its full potential failed to be expressed, owing to the nature of the material used for the MMV chip. RESULTS In the present study, by developing plastic-based MMVs and associated technologies, we introduced novel technologies such as C2D2P (in which the cells in each well are converted from DNA to protein in 1024-parallel), NGS-non-dependent microbiome analysis, and other powerful applications. CONCLUSIONS The reborn MMV-microarray technology has proven to be highly efficient and cost-effective (with approximately 100-fold cost reduction) and enables us to realize hitherto unattainable technologies.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Koichi Nishigaki
- Department of Functional Materials Science, Graduate School of Science and Engineering, Saitama University, 255 Shimo-okubo, Saitama 338-8570, Japan.
| |
Collapse
|
5
|
Smith T, Ho PI, Yue K, Itkin Z, MacDougall D, Paolucci M, Hill A, Auld DS. Comparison of compound administration methods in biochemical assays: effects on apparent compound potency using either assay-ready compound plates or pin tool-delivered compounds. ACTA ACUST UNITED AC 2012; 18:14-25. [PMID: 22904199 DOI: 10.1177/1087057112455434] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Compound sample preparation and delivery are the most critical steps in high-throughput screening (HTS) campaigns. Historically, several methods of compound delivery to assays have been used for HTS, including intermediate plates with prediluted compounds, assay-ready plates (ARPs) using either preplated dried compound films or nanoliter DMSO spots of compounds, as well as pin tool-delivered compounds. We and others have observed differences in apparent compound potency depending on the compound delivery method. To quantitatively measure compound potency differences due to the chosen delivery methods, we conducted a controlled study using a validated biochemical luciferase assay and compared potencies when compounds were delivered in either ARPs (using acoustic dispensed nanoliter spots) or by pin tool. Here we compare hit rates, confirmation rates, false-positive rates, and false-negative rates between the two delivery methods using the luciferase assay. We compared polystyrene (PS) and cyclic olefin copolymer (COC) plates using both delivery methods and examined whether ARPs stored at 4 °C were superior to those stored frozen at -20 °C. The data show that the choice of compound delivery method to the assay has an effect on the apparent IC(50)'s and that pin tool delivery results in more confirmed hits than preplated compounds, resulting in a lower false-negative rate. However, this effect is minimized through the use of COC plates and by obtaining plates in a "just-in-time" mode. Overall, this report provides guidance on using assay-ready compound plates and has affected the way HTS campaigns are using acoustically dispensed plates in our department.
Collapse
Affiliation(s)
- Thomas Smith
- Lead Finding Platform, Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Inc., Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Puccinelli JP, Su X, Beebe DJ. Automated high-throughput microchannel assays for cell biology: Operational optimization and characterization. ACTA ACUST UNITED AC 2010; 15:25-32. [PMID: 20209121 DOI: 10.1016/j.jala.2009.10.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Screening biological readouts in cell culture are increasing in frequency and throughput. In such assays, cell types may be rare and reagents or compounds may be expensive often resulting in a reduced number of conditions and/or replicates. "Tubeless" microfluidics offers a method to reduce this burden, as has been previously shown.1 In addition the In Cell Western (ICW) has recently been adapted to microfluidic cultures allowing high throughput analysis of immunocytochemistry (ICC) in microfluidic channels.2 Combining automated liquid handling in tubeless microfluidics with the ICW provides rapid and quantitative high throughput cell-based screens. Here we validate this platform using three parameters: operational robustness (pipetting reliability), cell seeding consistency, and cell staining consistency (both nuclear and antibody). Integration of liquid handling with microfluidics was found to be over 97% operationally robust. Cell seeding consistency between each microchannel and within each microchannel was found to be within a standard deviation of less than 5% and 6% respectively. Finally, through optimization of liquid handling steps, uniformity between all the channels was found for both nuclear and antibody staining. These results lay the foundation to perform most standard ICW assays using automated tubeless microfluidics.
Collapse
Affiliation(s)
- John P Puccinelli
- Department of Biomedical Engineering & Wisconsin Institutes for Medical Research, University of Wisconsin-Madison, Madison, WI 53726
| | | | | |
Collapse
|
7
|
Suzuki G, Kawamoto H, Ohta H. Development of a β-Lactamase Reporter Gene Assay for Metabotropic Glutamate Receptor 1 by Using Coexpression of Glutamate Transporter. ACTA ACUST UNITED AC 2010; 15:148-58. [DOI: 10.1177/1087057109356982] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
mGluR1 antagonists have been postulated to be novel CNS drugs, including antipsychotics. Toward this end, the authors developed a β-lactamase reporter assay to identify mGluR1 antagonists. β-Lactamase has several interesting features for high-throughput screening, including very high sensitivity and less well-to-well variation than other reporter enzymes. mGluR1-expressing Chinese hamster ovary (CHO) cells with the β-lactamase gene under control of the nuclear factor of activated T cells (NFAT) promoter (CHO-NFAT-bla-hmGluR1b) exhibited very high basal activity, resulting in an inadequate signal-to-basal (S/B) ratio. Coexpression of glutamate/aspartate transporter (GLAST) with mGluR1 in the cell line (CHO-NFAT-bla-hmGluR1b-GLAST) dramatically decreased basal activity and improved the S/B ratio (from 2- to 20-fold). The contribution of GLAST to lowering basal activity and increasing the S/B ratio was validated by the expression level of GLAST mRNA and by a GLAST inhibitor. Antagonistic activities of known mGluR1 antagonists in the β-lactamase reporter assay were comparable with those in the conventional Ca2+ mobilization assay. The Z′ factor of the β-lactamase reporter assay was 0.89 under optimized conditions. Taken together, the β-lactamase reporter assay with CHO-NFAT-bla-hmGluR1b-GLAST could be a novel high-throughput assay for mGluR1 antagonist screening. This is the first description of a successful β-lactamase reporter assay among all mGluR subtypes.
Collapse
Affiliation(s)
- Gentaroh Suzuki
- Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan
- Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi, Fukuoka, Japan
- Central Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, Japan
- Central Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, Japan
| | - Hiroshi Kawamoto
- Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan
| | - Hisashi Ohta
- Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan
| |
Collapse
|
8
|
Abstract
GPR23 is a G protein-coupled receptor (GPCR) proposed to play a vital role in neurodevelopment processes such as neurogenesis and neuronal migration. To date, no small molecule GPR23 agonists or antagonists have been reported, except for the natural ligand, lysophosphatic acid, and its analogs. Identification of ligands selective for GPR23 would provide valuable tools for studying the pharmacology, physiological function, and pathophysiological implications of this receptor. This report describes how a tetracycline-inducible system was utilized in conjunction with a sensitive β-lactamase reporter gene to develop an assay in which constitutive activity of the receptor could be monitored. This assay was then utilized to screen a 1.1 million compound library to identify the first small molecule inverse agonists for the receptor. We believe that these compounds will be invaluable tools in the further study of GPR23. In addition, we believe that the assay development techniques utilized in this report are broadly applicable to other receptors exhibiting constitutive activity.
Collapse
Affiliation(s)
- Paul H Lee
- Lead Discovery, Amgen, Inc., Thousand Oaks, California, USA
| | | |
Collapse
|
9
|
Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, Thorne N, Austin CP, Inglese J, Simeonov A. A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 2009; 6:637-57. [PMID: 19035846 DOI: 10.1089/adt.2008.150] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
High-throughput screening (HTS) is increasingly being adopted in academic institutions, where the decoupling of screening and drug development has led to unique challenges, as well as novel uses of instrumentation, assay formulations, and software tools. Advances in technology have made automated unattended screening in the 1,536-well plate format broadly accessible and have further facilitated the exploration of new technologies and approaches to screening. A case in point is our recently developed quantitative HTS (qHTS) paradigm, which tests each library compound at multiple concentrations to construct concentration-response curves (CRCs) generating a comprehensive data set for each assay. The practical implementation of qHTS for cell-based and biochemical assays across libraries of > 100,000 compounds (e.g., between 700,000 and 2,000,000 sample wells tested) requires maximal efficiency and miniaturization and the ability to easily accommodate many different assay formats and screening protocols. Here, we describe the design and utilization of a fully integrated and automated screening system for qHTS at the National Institutes of Health's Chemical Genomics Center. We report system productivity, reliability, and flexibility, as well as modifications made to increase throughput, add additional capabilities, and address limitations. The combination of this system and qHTS has led to the generation of over 6 million CRCs from > 120 assays in the last 3 years and is a technology that can be widely implemented to increase efficiency of screening and lead generation.
Collapse
Affiliation(s)
- Sam Michael
- NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20850, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Miyake M, Yoshikawa T, Fujita S, Miyake J. Transfection microarray™ and the applications. MOLECULAR BIOSYSTEMS 2009; 5:444-9. [DOI: 10.1039/b821731a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
Abstract
G protein-coupled receptors (GPCRs) are a large family of proteins that represent targets for approximately 40% of all approved drugs. They possess unique structural motifs that allow them to interact with a diverse series of extracellular ligands, as well as intracellular signaling proteins, such as G proteins, RAMPs, arrestins, and indeed other receptors. Extensive efforts are under way to discover new generations of drugs against GPCRs with unique targeted therapeutic uses, including "designer" drugs such as allosteric regulators, inverse agonists, and drugs targeting hetero-oligomeric complexes. This has been facilitated by the development of new screening technologies to identify novel drugs against both known and orphan GPCRs.
Collapse
|
12
|
Turner BA, Evans BP, Pearson TT, Braden TK, Wise SC. Examination of Edge Effects with Different Storage Conditions of Preplated Dimethyl Sulfoxide Nanospots in ChemLib 1,536- and 3,456-Well Assay-Ready Plates. Assay Drug Dev Technol 2008; 6:811-8. [DOI: 10.1089/adt.2008.169] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Benjamin A. Turner
- Department of Assay Technologies, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, Michigan
- Gilead Colorado, Westminster, Colorado
| | - Brad P. Evans
- Department of Statistics, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, Michigan
- Pfizer Global Research and Development, Groton, Connecticut
| | - Tania T. Pearson
- Department of Assay Technologies, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, Michigan
- Pfizer Global Research and Development, St. Louis, Missouri
| | - Timothy K. Braden
- Department of Assay Technologies, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, Michigan
- Pfizer Global Research and Development, St. Louis, Missouri
| | - Scott C. Wise
- Department of Assay Technologies, Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, Michigan
- Deciphera Pharmaceuticals, Lawrence, Kansas
| |
Collapse
|
13
|
Warrick JW, Murphy WL, Beebe DJ. Screening the cellular microenvironment: a role for microfluidics. IEEE Rev Biomed Eng 2008; 1:75-93. [PMID: 20190880 DOI: 10.1109/rbme.2008.2008241] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The cellular microenvironment is an increasingly discussed topic in cell biology as it has been implicated in the progression of cancer and the maintenance of stem cells. The microenvironment of a cell is an organized combination of extracellular matrix (ECM), cells, and interstitial fluid that influence cellular phenotype through physical, mechanical, and biochemical mechanisms. Screening can be used to map combinations of cells and microenvironments to phenotypic outcomes in a way that can help develop more predictive in vitro models and to better understand phenotypic mechanisms from a systems biology perspective. This paper examines microenvironmental screening in terms of outcomes and benefits, key elements of the screening process, challenges for implementation, and a possible role for microfluidics as the screening platform. To assess microfluidics for use in microenvironmental screening, examples and categories of micro-scale and microfluidic technology are highlighted. Microfluidic technology shows promise for simultaneous control of multiple parameters of the microenvironment and can provide a base for scaling advanced cell-based experiments into automated high-throughput formats.
Collapse
Affiliation(s)
- Jay W Warrick
- Department of Biomedical Engineering, University of Wisconsin, Madison, WI 53706-1609, USA
| | | | | |
Collapse
|
14
|
Chung CC, Ohwaki K, Schneeweis JE, Stec E, Varnerin JP, Goudreau PN, Chang A, Cassaday J, Yang L, Yamakawa T, Kornienko O, Hodder P, Inglese J, Ferrer M, Strulovici B, Kusunoki J, Tota MR, Takagi T. A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production. Assay Drug Dev Technol 2008; 6:361-74. [PMID: 18452391 DOI: 10.1089/adt.2007.105] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Here we report the development and miniaturization of a cell-free enzyme assay for ultra-high-throughput screening (uHTS) for inhibitors of two potential drug targets for obesity and cancer: fatty acid synthase (FAS) and acetyl-coenzyme A (CoA) carboxylase (ACC) 2. This assay detects CoA, a product of the FAS-catalyzed condensation of malonyl-CoA and acetyl-CoA. The free thiol of CoA can react with 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM), a profluorescent coumarin maleimide derivative that becomes fluorescent upon reaction with thiols. FAS produces long-chain fatty acid and CoA from the condensation of malonyl-CoA and acetyl-CoA. In our FAS assay, CoA released in the FAS reaction forms a fluorescence adduct with CPM that emits at 530 nm when excited at 405 nm. Using this detection method for CoA, we measured the activity of sequential enzymes in the fatty acid synthesis pathway to develop an ACC2/FAS-coupled assay where ACC2 produces malonyl-CoA from acetyl-CoA. We miniaturized the FAS and ACC2/FAS assays to 3,456- and 1,536-well plate format, respectively, and completed uHTSs for small molecule inhibitors of this enzyme system. This report shows the results of assay development, miniaturization, and inhibitor screening for these potential drug targets.
Collapse
Affiliation(s)
- Christine C Chung
- Department of Metabolic Disorders, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Bergsdorf C, Kropp-Goerkis C, Kaehler I, Ketscher L, Boemer U, Parczyk K, Bader B. A One-Day, Dispense-Only IP-One HTRF Assay for High-Throughput Screening of Gαq Protein-Coupled Receptors: Towards Cells as Reagents. Assay Drug Dev Technol 2008; 6:39-53. [DOI: 10.1089/adt.2007.108] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Christian Bergsdorf
- Department of Screening, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| | - Carmen Kropp-Goerkis
- Department of Screening, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| | - Irene Kaehler
- Department of Protein Supply, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| | - Lars Ketscher
- Institute of Zoology, Technical University, Dresden, Germany
| | - Ulf Boemer
- Department of Screening, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| | - Karsten Parczyk
- Department of Screening, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| | - Benjamin Bader
- Department of Screening, Lead Discovery Berlin, Bayer Schering Pharma AG, Berlin, Germany
| |
Collapse
|
16
|
Eglen RM, Bosse R, Reisine T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay Drug Dev Technol 2007; 5:425-51. [PMID: 17638542 DOI: 10.1089/adt.2007.062] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Guanine nucleotide binding protein (G protein) coupled receptors (GPCRs) comprise one of the largest families of proteins in the human genome and are a target for 40% of all approved drugs. GPCRs have unique structural motifs that allow them to interact with a wide and diverse series of extracellular ligands, as well as intracellular proteins, G proteins, receptor activity-modifying proteins, arrestins, and indeed other receptors. This distinctive structure has led to numerous efforts to discover drugs against GPCRs with targeted therapeutic uses. Such "designer" drugs currently include allosteric regulators, inverse agonists, and drugs targeting hetero-oligomeric complexes. Moreover, the large family of orphan GPCRs provides a rich and novel field of targets to discover drugs with unique therapeutic properties. The numerous technologies to discover GPCR drugs have also greatly advanced over the years, facilitating compound screening against known and orphan GPCRs, as well as in the identification of unique designer GPCR drugs. Indeed, high throughput screening (HTS) technologies employing functional cell-based approaches are now widely used. These include measurement of second messenger accumulation such as cyclic AMP, calcium ions, and inositol phosphates, as well as mitogen-activated protein kinase activation, protein-protein interactions, and GPCR oligomerization. This review focuses on how the improved understanding of the molecular pharmacology of GPCRs, coupled with a plethora of novel HTS technologies, is leading to the discovery and development of an entirely new generation of GPCR-based therapeutics.
Collapse
Affiliation(s)
- Richard M Eglen
- Discovery and Research Reagents, PerkinElmer Life and Analytical Sciences, Waltham, MA 02451, USA.
| | | | | |
Collapse
|
17
|
Weber M, Muthusubramaniam L, Murray J, Hudak E, Kornienko O, Johnson EN, Strulovici B, Kunapuli P. Ultra-High-Throughput Screening for Antagonists of A Gi-Coupled Receptor in A 2.2-μl 3,456-Well Plate Format CyclicAMP Assay. Assay Drug Dev Technol 2007; 5:117-25. [PMID: 17355204 DOI: 10.1089/adt.2006.043] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
3',5'-Cyclic adenosine monophosphate (cAMP) is a common intracellular second messenger that enables cells to respond to external stimuli. Measurement of intracellular cAMP concentrations is thus widely used for studying guanosine triphosphate binding protein-coupled receptors (GPCRs), which make up a large class of pharmaceutical drug targets. Although several assay technologies exist to measure cAMP, most are not suitable for ultra-high-throughput screening (uHTS), as is often required for screening large (greater than 1 million) chemical libraries for the identification of suitable leads for drug development. Here we report that the enzyme fragment complementation assay, a homogeneous gain of signal assay based on complementation of two fragments of a beta-galactosidase enzyme, is compatible with uHTS requirements of a 2.2-microl total assay volume in 3,456-well plate format. We describe the miniaturization of this assay into 3,456-well plate format exhibiting comparable sensitivity and plate statistics to those of a 384-well assay and the application of this assay in uHTS for the identification of antagonists of a Gi-coupled receptor.
Collapse
Affiliation(s)
- Michael Weber
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Qureshi SA. β-Lactamase: an ideal reporter system for monitoring gene expression in live eukaryotic cells. Biotechniques 2007; 42:91-6. [PMID: 17269490 DOI: 10.2144/000112292] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
To gain insightful information about the mechanisms through which genes are activated and repressed requires gene reporter systems that are sensitive, robust, and cost-effective. Although numerous reporter gene technologies are commercially available, none are as sophisticated and user-friendly as β-lactamase (BLA) when it comes to studying gene expression in live cells. This article presents an overview of the BLA technology and describes how it can be exploited for studying rare events such as homologous recombination in somatic cells and be used to deliver any DNA sequence of choice anywhere within the genome.
Collapse
Affiliation(s)
- Sohail A Qureshi
- Department of Biological & Biomedical Sciences, The Aga Khan University Hospital, Karachi, Pakistan.
| |
Collapse
|
19
|
Marine S, Zamiara E, Smith ST, Stec EM, McGarvey J, Kornienko O, Jiang G, Wong KK, Stack JH, Zhang BB, Ferrer M, Strulovici B. A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation. Anal Biochem 2006; 355:267-77. [PMID: 16797469 DOI: 10.1016/j.ab.2006.05.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2006] [Revised: 05/09/2006] [Accepted: 05/13/2006] [Indexed: 10/24/2022]
Abstract
This report describes the development, optimization, and implementation of a miniaturized cell-based assay for the identification of small-molecule insulin mimetics and potentiators. Cell-based assays are attractive formats for compound screening because they present the molecular targets in their cellular environment. A fluorescence resonance energy transfer (FRET) cell-based assay that measures the insulin-dependent colocalization of Akt2 fused with either cyan fluorescent protein or yellow fluorescent protein to the cellular membrane was developed. This ratiometric FRET assay was miniaturized into a robust, yet sensitive 3456-well nanoplate assay with Z' factors of approximately 0.6 despite a very small assay window (less than twofold full activation with insulin). The FRET assay was used for primary screening of a large compound collection for insulin-receptor agonists and potentiators. To prioritize compounds for further development, primary hits were tested in two additional assays, a biochemical time-resolved fluorescence resonance energy transfer assay to measure insulin-receptor phosphorylation and a translocation-based imaging assay. Results from the three assays were combined to yield 11 compounds as potential leads for the development of insulin mimetics or potentiators.
Collapse
Affiliation(s)
- Shane Marine
- Department of Automated Biotechnology, Merck & Co., Inc., 502 Louise Lane, North Wales, PA 19454, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The term 'receptorome' is now being used to describe receptors, ion channels and transporters in the human genome that are potential drug targets. These proteins comprise a considerable fraction of the human genome, and include the G protein-coupled receptors, which are the targets for many medications. In this review, we summarize recent advances in the field, including the concept that the ultimate goal of drug discovery may not be the development of highly selective single-target drugs, the idea that potential side-effects can also be the goal of multi-target drug screening, and a discussion of the application of computational screening and public domain databases available to interested investigators.
Collapse
Affiliation(s)
- Wesley K Kroeze
- Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, OH 44106, USA
| | | |
Collapse
|
21
|
Brandish PE, Chiu CS, Schneeweis J, Brandon NJ, Leech CL, Kornienko O, Scolnick EM, Strulovici B, Zheng W. A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase. ACTA ACUST UNITED AC 2006; 11:481-7. [PMID: 16760370 DOI: 10.1177/1087057106288181] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Enzymes are often considered less “druggable” targets than ligand-regulated proteins such as G-protein-coupled receptors, ion channels, or other hormone receptors. Reasons for this include cellular location (intracellular vs. cell surface), typically lower affinities for the binding of small molecules compared to ligand-specific receptors, and binding (catalytic) sites that are often charged or highly polar. A practical drawback to the discovery of compounds targeting enzymes is that screening of compound libraries is typically carried out in cell-free activity assays using purified protein in an inherently artificial environment. Cell-based assays, although often arduous to design for enzyme targets, are the preferred discovery tool for the screening of large compound libraries. The authors have recently described a novel cell-based approach to screening for inhibitors of a phosphatase enzyme and now report on the development and implementation of a homogeneous 3456-well plate assay for D-amino acid oxidase (DAO). Human DAO was stably expressed in Chinese hamster ovary (CHO) cells, and its activity was measured as the amount of hydrogen peroxide detected in the growth medium following feeding the cells with D-serine. In less than 12 weeks, the authors proved the concept in 96-and then 384-well formats, miniaturized the assay to the 3456-well (nanoplate) scale, and screened a library containing more than 1 million compounds. They have identified several cell-permeable inhibitors of DAO from this cell-based high-throughput screening, which provided the discovery program with a few novel and attractive lead structures.
Collapse
|
22
|
Kunapuli P, Lee S, Zheng W, Alberts M, Kornienko O, Mull R, Kreamer A, Hwang JI, Simon MI, Strulovici B. Identification of small molecule antagonists of the human mas-related gene-X1 receptor. Anal Biochem 2006; 351:50-61. [PMID: 16510108 DOI: 10.1016/j.ab.2006.01.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2005] [Revised: 12/22/2005] [Accepted: 01/09/2006] [Indexed: 11/25/2022]
Abstract
The recently identified mas-related-gene (MRG) family of receptors, located primarily in sensory neurons of the dorsal root ganglion, has been implicated in the perception of pain. Thus, antagonists of this class of receptors have been postulated to be useful analgesics. Toward this end, we developed a cell-based beta-lactamase (BLA) reporter gene assay to identify small molecule antagonists of the human MRG-X1 receptor from a library of compounds. Single-cell clones expressing functional receptors were selected using the BLA reporter gene technology. The EC50 for the MRG agonist peptide, BAM15, appeared to be comparable between the BLA assay and the intracellular Ca2+ transient assays in these cells. Ultra high-throughput screening of approximately 1 million compounds in a 1.8-microl cell-based BLA reporter gene assay was conducted in a 3456-well plate format. Compounds exhibiting potential antagonist profile in the BLA assay were confirmed in the second messenger Ca2+ transient assay. A cell-based receptor trafficking assay was used to further validate the mechanism of action of these compounds. Several classes of compounds, particularly the 2,3-disubstituted azabicyclo-octanes, appear to be relatively potent antagonists at the human MRG-X1 receptors, as confirmed by the receptor trafficking assay and radioligand binding studies. Furthermore, the structure-activity relationship reveals that within this class of compounds, the diphenylmethyl moiety is constant at the 2-substituent, whereas the 3-substituent is directly correlated with the antagonist activity of the compound.
Collapse
Affiliation(s)
- Priya Kunapuli
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Niles WD, Coassin PJ. Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. Assay Drug Dev Technol 2005; 3:189-202. [PMID: 15871693 DOI: 10.1089/adt.2005.3.189] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Miniaturization of biological assays requires dispensing liquids in the submicroliter range of volumes. Accuracy and reproducibility of dispensing this range depend on both the dispenser and the receptacle in which the assay is constructed. Miniaturization technologies developed by Aurora Discovery, Inc. (San Diego, CA) include high-density multiwell plates for assay samples and reagent storage, as well as piezo-based and solenoid valve-based liquid dispensers. Some basic principles of small-volume dispensing by jetting are described to provide context for dispenser design and function. Performance of the latest instruments incorporating these dispensing devices is presented.
Collapse
|
24
|
Shi X, Zheng W, Schneeweis JE, Fischer PA, Strulovici B, Peekhaus NT. A Short-Incubation Reporter-Gene Assay for High-Throughput Screening of Estrogen Receptor-α Antagonists. Assay Drug Dev Technol 2005; 3:393-400. [PMID: 16180994 DOI: 10.1089/adt.2005.3.393] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Estrogen receptor (ER) alpha and beta are ligand-activated nuclear transcription factors that mediate the effects of the steroid hormone 17beta-estradiol. Tissue-selective ER modulators have been developed for the treatment of a variety of diseases, including osteoporosis and hormone-dependent breast cancer. Second- and third-generation selective ER modulators are in development, with the goal of reducing toxicity and improving tissue-selective efficacy. Novel tissue-selective and ERsubtype specific ligands may have the potential of providing a new paradigm for maintaining the health of women. The traditional cell-based screening assays for nuclear receptors require 16-18 h of incubation, which limits the assay miniaturization for ultra-high-throughput screening. We have developed a new cell-based ERalpha transactivation assay for the screening of ERalpha-specific antagonists with only 4 h of incubation time. The assay was optimized and used for a fully automated ultrahigh-throughput screen in 3,456-well nanoplate format. The screening throughput was 250,000-300,000 compounds per day, and a number of valuable leads were identified.
Collapse
Affiliation(s)
- Xiaoqing Shi
- Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA, USA
| | | | | | | | | | | |
Collapse
|
25
|
Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M. A cell-based β-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Anal Biochem 2004; 334:344-55. [PMID: 15494142 DOI: 10.1016/j.ab.2004.07.031] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2004] [Indexed: 10/26/2022]
Abstract
This report describes the development, optimization, and implementation of a cell-based assay for high-throughput screening (HTS) to identify inhibitors to hepatitis C virus (HCV) replication. The assay is based on a HCV subgenomic RNA replicon that expresses beta-lactamase as a reporter for viral replication in enhanced Huh-7 cells. The drug targets in this assay are viral and cellular enzymes required for HCV replication, which are monitored by fluorescence resonance energy transfer using cell-permeable CCF4-AM as a beta-lactamase substrate. Digital image processing was used to visualize cells that harbor viral RNA and to optimize key assay development parameters such as transfection and culturing conditions to obtain a cell line which produced a robust assay window. Formatting the assay for compound screening was problematic due to small signal-to-background ratio and reduced potency to known HCV inhibitors. These technical difficulties were solved by using clavulanic acid, an irreversible inhibitor of beta-lactamase, to eliminate residual beta-lactamase activity after HCV replication was terminated, thus resulting in an improved assay window. HTS was carried out in 384-well microplate format, and the signal-to-background ratio and Z factor for the assay plates during the screen were approximately 13-fold and 0.5, respectively.
Collapse
Affiliation(s)
- Paul Zuck
- Department of Automated Biotechnology, Merck and Co., 502 Louise Lane., North Wales, PA 19454, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|